The scientist’s investigation covers issues in Internal medicine, Breast cancer, Cancer research, Urokinase and Plasminogen activator. His Internal medicine research includes elements of Endocrinology and Oncology. Breast cancer is the subject of his research, which falls under Cancer.
His biological study spans a wide range of topics, including Cell, Gene expression and Plasmin. His studies deal with areas such as Survival rate, Primary tumor and Immunology as well as Urokinase. He has researched Plasminogen activator in several fields, including Proteases, Node negative and Antigen.
His primary areas of study are Internal medicine, Breast cancer, Cancer research, Plasminogen activator and Oncology. His work on Endocrinology expands to the thematically related Internal medicine. The various areas that he examines in his Breast cancer study include Immunology, Chemotherapy and Pathology.
Manfred Schmitt interconnects Cancer cell, Tumor progression, Cell and In vivo in the investigation of issues within Cancer research. The concepts of his Plasminogen activator study are interwoven with issues in Proteases, Plasmin and Urokinase. Manfred Schmitt works mostly in the field of Oncology, limiting it down to concerns involving DNA methylation and, occasionally, Methylation.
Manfred Schmitt mainly investigates Breast cancer, Cancer research, Oncology, Internal medicine and Pathology. His Breast cancer study is related to the wider topic of Cancer. His Cancer research research is multidisciplinary, incorporating perspectives in Cancer cell, Immunology, Urokinase receptor, Ovarian cancer and Triple-negative breast cancer.
His study in Oncology is interdisciplinary in nature, drawing from both Hazard ratio, Anthracycline, Lymph node, Endocrine system and Biomarker. His biological study focuses on Cohort. His Pathology study also includes
Cancer research, Breast cancer, Pathology, Metastasis and Cancer are his primary areas of study. His Cancer research research integrates issues from CXCL10, CXCL9, Cancer cell, Ovarian cancer and microRNA. The Breast cancer study combines topics in areas such as HEK 293 cells, Tumor progression, Proteomics and Cell growth.
His Metastasis research is classified as research in Internal medicine. His Clinical Oncology, Node negative and Plasminogen activator study, which is part of a larger body of work in Internal medicine, is frequently linked to Risk assessment, bridging the gap between disciplines. His Cancer study combines topics in areas such as Lung and Human genetics.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients.
Maxime P. Look;Wim L. J. van Putten;Michael J. Duffy;Nadia Harbeck.
Journal of the National Cancer Institute (2002)
BCR-ABL Maintains Resistance of Chronic Myelogenous Leukemia Cells to Apoptotic Cell Death
Anne McGahon;Reid Bissonnette;Reid Bissonnette;Manfred Schmitt;Manfred Schmitt;Kate M. Cotter;Kate M. Cotter.
Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1.
F. Janicke;A. Prechtl;C. Thomssen;N. Harbeck.
Journal of the National Cancer Institute (2001)
Increased Neutrophil-Platelet Adhesion in Patients With Unstable Angina
I Ott;F J Neumann;M Gawaz;M Schmitt.
The Urokinase System of Plasminogen Activation and Prognosis in 2780 Breast Cancer Patients
J. A. Foekens;H. A. Peters;M. P. Look;H. Portengen.
Cancer Research (2000)
Clinical impact of the plasminogen activation system in tumor invasion and metastasis : Prognostic relevance and target for therapy
M Schmitt;N Harbeck;C Thomssen;O Wilhelm.
Thrombosis and Haemostasis (1997)
Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer
Fritz Jänicke;Manfred Schmitt;Lothar Pache;Kurt Ulm.
Breast Cancer Research and Treatment (1993)
Increased Expression of Matrix Metalloproteinases (MMP)-2, MMP-9, and the Urokinase-Type Plasminogen Activator Is Associated with Progression from Benign to Advanced Ovarian Cancer
Barbara Schmalfeldt;Dieter Prechtel;Kathrin Härting;Kerstin Späthe.
Clinical Cancer Research (2001)
Rac1 in human breast cancer: overexpression, mutation analysis, and characterization of a new isoform, Rac1b.
A Schnelzer;D Prechtel;U Knaus;K Dehne.
Cathepsin B efficiently activates the soluble and the tumor cell receptor-bound form of the proenzyme urokinase-type plasminogen activator (Pro-uPA).
H Kobayashi;M Schmitt;L Goretzki;N Chucholowski.
Journal of Biological Chemistry (1991)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: